There was a problem loading this presentation. You may not have permission to view it.

You do not have permission to view this presentation.

Use of immuno-oncology


An error occurred while loading this content.

Please refresh the page to try again.

Refresh Now
You previously started this content
Login or join to view
Click to Play

Use of immuno-oncology

The texts for this project were developed in cooperation with the members of our Advisory Board.
• Prof. Dr. med. Salah Eddin Al-Batran, Frankfurt am Main (Germany)
• Prof. Dr. med. Diana Lüftner, Berlin (Germany)
• Amel M’sadek, (Oncology Nurse and Member of the French Association of Oncology Nurses (AFIC)), Rennes Cedex (France)
• Marion Mecklenborg, (Oncology Nurse), Bremen (Germany)
• Dr. ssa. Alessandra Milani, (Oncology Nurse), Milan (Italy)
• Maria Paz Fernández Ortega, (Oncology Nurse), Barcelona (Spain)
• Julia Williams, (Oncology Nurse), Berks (England)

This module explains which types of cancer are treated with immuno-oncological treatments, and also discusses the side effects associated with new immuno-oncological agents.

1. Evan J. Lipson Charles G. Drake: Ipilimumab: an Anti-CTLA-4 Antibody for Metastatic Melanoma;  Clin. Cancer Res. 17, Nr. 22, 2011, S. 6958–62.

2. Ribas A et al; Efficacy and Safety of the anti-PD-1 monoclonal antibody mk-3475 in 411 patients with melanoma; J Clin Oncol 2014, 32 (18 Suppl 1): LBA9000

3. Robert C et al; Pembrolizumab versus Ipilimumab in Advanced Melanoma; N Engl J Med April 2015 (online first)

4. Rawyn M Poole et al; Pembrolizumab: First Global Approval; Drugs (2014) 74: 1973-1981

5. Amos S et al. Autoimmunity associated with immunotherapy of cancer. Blood 2011. doi: 10.1182/blood-2011-01-325266.

6. Pardoll DM et al; The blockade of immune checkpoints in cancer immunotherapy.Nat Rev Cancer 2012; 12(4): 252-65; doi: 10.1038/nrc3239

7. Patsoukis N et al; Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation; Science Signal (2012); Vol. 5, Issue 230, p. ra46.

Responsible for the content: © 2015 KWHC GmbH, Alewinstr. 13, 29525 Uelzen (Germany). The image sources can be found at:

Latest expert presentations

View more